|
KMID : 0620920190510120161
|
|
Experimental & Molecular Medicine
2019 Volume.51 No. 12 p.161 ~ p.161
|
|
|
Heart failure with preserved ejection fraction: present status and future directions
|
|
Yoon So-My
Eom Gwang-Hyeon
|
|
|
Abstract
|
|
|
|
The clinical importance of heart failure with preserved ejection fraction (HFpEF) has recently become apparent. HFpEF refers to heart failure (HF) symptoms with normal or near-normal cardiac function on echocardiography. Common clinical features of HFpEF include diastolic dysfunction, reduced compliance, and ventricular hypokinesia. HFpEF differs from the better-known HF with reduced ejection fraction (HFrEF). Despite having a “preserved ejection fraction,” patients with HFpEF have symptoms such as shortness of breath, excessive tiredness, and limited exercise capability. Furthermore, the mortality rate and cumulative survival rate are as severe in HFpEF as they are in HFrEF. While beta-blockers and renin-angiotensin-aldosterone system modulators can improve the survival rate in HFrEF, no known therapeutic agents show similar effectiveness in HFpEF. Researchers have examined molecular events in the development of HFpEF using small and middle-sized animal models. This review discusses HFpEF with regard to etiology and clinical features and introduces the use of mouse and other animal models of human HFpEF.
|
|
|
KEYWORD
|
|
|
Heart failure, Translational research
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|